Cognitive Medication Avoidance After TBI: Evidence for PI Attorneys

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 9 min read

After a traumatic brain injury, prescribers must avoid medications that impair cognition — including many standard pain management drugs. This forced avoidance of effective medications is itself evidence of TBI severity and creates treatment limitations that increase the complexity, cost, and duration of post-injury care in ways PI attorneys should document.

Cognitive Medication Avoidance After TBI: Evidence for PI Attorneys

After a traumatic brain injury (TBI), prescribers face a clinical constraint that does not exist in most other personal injury cases: they must avoid or limit medications that impair cognition. Opioids, benzodiazepines, sedating muscle relaxants, first-generation antihistamines, and anticholinergic medications — drugs that are commonly prescribed for pain, anxiety, and muscle spasm in PI cases — carry cognitive side effects that can worsen or mask TBI-related cognitive deficits. The resulting medication avoidance is itself clinical evidence of TBI severity, and the treatment limitations it creates should be documented as part of the damages narrative.

• TBI patients must avoid cognitively impairing medications that are standard treatment for other PI injury types
• This forced avoidance narrows available treatment options, often requiring more expensive or complex alternatives
• The prescriber's decision to avoid cognitive-impairing drugs is clinical documentation of TBI severity
• Treatment of comorbid conditions (pain, anxiety, insomnia) becomes more difficult and costly when cognitive protection is required
• As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, the medications a TBI patient cannot take are as important as the medications they do take when building the damages narrative

Why Cognitive Medication Avoidance Matters

In a typical PI case involving musculoskeletal injuries, the prescriber has a full pharmacological toolkit: opioids for acute pain, benzodiazepines for anxiety and muscle spasm, sedating antihistamines for sleep, muscle relaxants for spasm, and anticholinergic medications as needed. These are effective, well-understood treatments.

In a TBI case, many of these standard tools are off-limits because their cognitive side effects can:

Worsen existing cognitive deficits. Opioids impair attention, memory, and processing speed. In a patient already experiencing TBI-related cognitive impairment, adding opioid-induced cognitive suppression creates a compounded deficit that may interfere with cognitive rehabilitation.

Mask cognitive recovery. If a TBI patient takes sedating medications, neuropsychological testing cannot accurately measure the patient's true cognitive function. Medication-induced cognitive impairment is clinically indistinguishable from injury-induced impairment on many standard tests.

Interfere with neuroplasticity. Emerging evidence suggests that certain CNS depressants may interfere with the neuroplastic recovery processes that are critical in the months following TBI. Minimizing cognitive suppression may support better long-term recovery.

Increase fall risk. TBI patients already have impaired balance and coordination. Adding medications that cause dizziness, sedation, or orthostatic hypotension creates unacceptable fall risk.

The Treatment Limitation as Evidence

When a prescriber documents that they are avoiding opioids "due to TBI" or selecting a non-sedating alternative "to protect cognitive function," that clinical decision is evidence of TBI severity. The prescriber is explicitly acknowledging that the brain injury is severe enough to constrain the treatment of other conditions.

This creates a documentation opportunity that many attorneys overlook. Every medication avoidance decision in a TBI case should be captured and presented as part of the damages narrative:

"Cannot use benzodiazepines for documented anxiety disorder due to TBI-related cognitive vulnerability." This documents both the anxiety condition and the TBI severity that prevents standard treatment.

"Switched from opioid to non-opioid pain management to protect cognitive rehabilitation progress." This documents pain severity (requiring management) and TBI severity (requiring cognitive protection).

"Selected more expensive non-sedating alternative due to TBI contraindication for standard sedating options." This documents why the treatment costs more than a non-TBI case with the same pain conditions.

Alternative Medications and Their Implications

When standard cognitive-impairing medications are contraindicated, prescribers must select alternatives:

For pain: Non-opioid analgesics including nerve blocks, topical agents, non-sedating antidepressants for neuropathic pain (duloxetine, venlafaxine), and newer non-opioid agents. These alternatives are often more expensive and may require specialist management.

For anxiety: Non-benzodiazepine anxiolytics such as buspirone, SSRIs, or SNRIs. These take longer to reach therapeutic effect and require more monitoring during titration.

For insomnia: Non-sedating sleep hygiene approaches, melatonin, or carefully selected low-dose agents that minimize cognitive impact. Effective insomnia management without cognitive impairment is clinically challenging.

For muscle spasm: Non-sedating approaches including physical therapy, topical muscle relaxants, and targeted interventions rather than systemic muscle relaxants.

Each alternative typically costs more, requires more specialist involvement, and takes longer to achieve therapeutic effect than the standard medication it replaces.

MERIT Documentation in TBI Cases

LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages. In TBI cases, the MERIT documentation specifically addresses cognitive medication avoidance, explaining which medications were not used and why, and documenting the clinical rationale for the alternative treatment selections.

This pharmacist-level documentation is particularly valuable because it provides expert clinical context for what might otherwise appear to be unusual prescribing choices. For more on how pharmacist documentation strengthens the clinical narrative, see Pharmacist Drug Interaction Interventions as PI Evidence.

The Compound Effect

TBI rarely occurs in isolation in PI cases. A motor vehicle accident that causes TBI typically also causes musculoskeletal injuries, pain, anxiety, and sleep disruption. Each of these comorbid conditions requires medication management, and each is constrained by the TBI-related need to avoid cognitive impairment. The compound effect — multiple conditions all requiring treatment within cognitive safety constraints — creates a treatment complexity level that far exceeds what either condition alone would require.

For additional discussion of how treatment complexity supports damages, see Medication Regimen Complexity Index Scoring.

Contact LienScripts to discuss how pharmacist review supports TBI medication management and documentation in your cases.